tailieunhanh - Báo cáo y học: " T cell activity in successful treatment of chronic urticaria with omalizumab"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: T cell activity in successful treatment of chronic urticaria with omalizumab. | Sánchez-Machín et al. Clinical and Molecular Allergy 2011 9 11 http content 9 1 11 CMA CLINICAL AND MOLECULAR ALLERGY COMMENTARY Open Access T cell activity in successful treatment of chronic urticaria with omalizumab Inmaculada Sanchez-Machin 1 Javier Iglesias-Souto1 Andrés Franco2 Yvelise Barrios2 Ruperto Gonzalez1 and Victor Matheu1 3 4 5 6 Abstract Omalizumab a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently it has been postulated the assessment of PHA-stimulated adenosine triphosphate ATP activity as maker of CD4 T cells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronic idiopathic urticaria and angioedema of 8 years of development with poor response to treatment. The patient was partially controlled with cyclosporine at doses of 100 mg 12 h. However she was still developing hives daily. Finally treatment with omalizumab was started at dose of 300 mg every 2 weeks. The patient experienced a decrease in urticarial lesions 2 days after starting therapy. We also evaluated the effects of omalizumab therapy on the activity of peripheral blood CD4 T cells from the patient in order to determine the potential modification of anti-IgE therapy on the process of antigen presentation-recognition. Activity of CD4 cells by ATP release was clearly increased demonstrating an enlarged CD4 activity. Omalizumab may be useful in the treatment of severe chronic urticaria. ATP activity of peripheral blood CD4 T cells might be a non-subjective method to assess Omalizumab activity. We have read the interesting manuscript recently published in Clinical and Molecular Allergy entitled Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab 1 . The study demonstrated the effectiveness of omalizumab in treating chronic idiopathic urticaria and the temporal relationship .